The study of ALT in cancer has mostly relied on ALT sarcoma cell lines (Heaphy et al., 2011) and their telomerase positive counterparts, and only recently TMMs started to be evaluated in primary cancers (Pompili et al., 2017). The gene discussed is GPT; the disease is sarcoma.